Proteomics Peptides & KitsPeptide sets and pools, as well as assay standardization kits are available with stable isotope labeled or unlabeled proteotypic peptides for mass-spectrometry based proteomics such as MRM assays.

Chelate Peptides (DOTA)DOTA is linked to molecules that have affinity for various structures (e.g. somatostatin receptors in neuroendocrine tumors). The resulting compounds can be bound to radionuclided and are used with a number of radioisotopes in cancer therapy and diagnosis

Immunology Standards & ControlsStandards and controls for reproducible T-cell assays such as ELISPOT and multimer assays. We offer a large variety of positive and negative control peptide pools for antigen specific T cell stimulation as well as kit to produce TCR-engineered reference samples for performance control.

Antigen PeptidesAntigen peptides represent specific epitopes for stimulation of T cells in T cell assays such as ELISPOT. We offer the corresponding MHC multimer for each antigen peptide. Antigens from different pathogens are available as well as tumor associated antigens.

Cosmetic PeptidesCosmetic Peptides such as Lysine and Cysteine Peptide are used for DPRA (Direct Peptide Reactivity Assay) for Skin Sensitization Testing. The DPRA measures the reaction of a chemical with synthetic peptides containing Cysteine (Ac‑RFAACAA‑COOH) or Lysine (Ac‑RFAAKAA‑COOH) to assess its sensitization potency. For research use only!

Tendeloo et al., PNAS (2010) - PMID: 20631300

Active immunization using tumor antigen-loaded dendritic cells holds promise for the adjuvant treatment of cancer to eradicate or control residual disease, but so far, most dendritic cell trials have been performed in end-stage cancer patients with high tumor loads. Here, in a phase I/II trial, we investigated the effect of autologous dendritic cell vaccination in 10 patients with acute myeloid leukemia (AML). The Wilms' tumor 1 protein (WT1), a nearly universal tumor antigen, was chosen as an immunotherapeutic target because of its established role in leukemogenesis and superior immunogenic characteristics. Two patients in partial remission after chemotherapy were brought into complete remission after intradermal administration of full-length WT1 mRNA-electroporated dendritic cells. In these two patients and three other patients who were in complete remission, the AML-associated tumor marker returned to normal after dendritic cell vaccination, compatible with the induction of molecular remission. Clinical responses were correlated with vaccine-associated increases in WT1-specific CD8+ T cell frequencies, as detected by peptide/HLA-A*0201 tetramer staining, and elevated levels of activated natural killer cells postvaccination. Furthermore, vaccinated patients showed increased levels of WT1-specific IFN-gamma-producing CD8+ T cells and features of general immune activation. These data support the further development of vaccination with WT1 mRNA-loaded dendritic cells as a postremission treatment to prevent full relapse in AML patients.